Compare TREX & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TREX | EWTX |
|---|---|---|
| Founded | 1996 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.9B | 3.3B |
| IPO Year | 1998 | 2021 |
| Metric | TREX | EWTX |
|---|---|---|
| Price | $39.26 | $32.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 6 |
| Target Price | ★ $49.53 | $39.00 |
| AVG Volume (30 Days) | ★ 1.9M | 1.2M |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.58 | N/A |
| Revenue | ★ $1,174,267,000.00 | N/A |
| Revenue This Year | $5.09 | N/A |
| Revenue Next Year | $6.24 | N/A |
| P/E Ratio | $66.77 | ★ N/A |
| Revenue Growth | ★ 1.98 | N/A |
| 52 Week Low | $29.77 | $12.31 |
| 52 Week High | $68.78 | $39.96 |
| Indicator | TREX | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.15 | 47.86 |
| Support Level | $35.25 | $27.81 |
| Resistance Level | $44.76 | $35.00 |
| Average True Range (ATR) | 2.00 | 1.69 |
| MACD | -0.04 | -0.27 |
| Stochastic Oscillator | 40.30 | 15.66 |
Trex Co Inc is a manufacturer of wooden alternative decking products. The company offers outdoor products in the decking, railing, porch, fencing, trim, steel deck framing, and outdoor lighting categories. Its products are sold under the Trex brand and manufactured in the United States. Further, the company licenses its Trex brand to third parties to manufacture and sell products under the Trex trademark. The distribution is focused on wholesale distributors and retail lumber dealers, which in turn sell Trex products to homeowners and contractors, with an emphasis on professional contractors, remodelers, and homebuilders. The company operates in one reportable segment i.e. Trex Residential.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.